• Date: July 24, 2018

Spanish biotechnology companies received €149 million last year, 17% more than in 2016. The sectors economic impact was worth 0.7% of Spanish GDP (€7.3 billion), and helped create over 108,000 jobs. These are some of the conclusions reached in the latest Annual Report published by the Spanish Association of Biotech Companies (ASEBIO).

In a breakdown by type of financial operation, the report highlights €93.7 million spent on increased private equity investments, €41 million in share capital increases, and €10.8 million on related operations and participation loans. There were also significant levels of venture capital activity in 2017, with entities in the sector, such as Caixa Capital Risc, investing a total of €30 million.

The report also provides data from the 2016 Innovation in Companies Survey carried out by the Spanish National Statistics Institute, showing that €617 million were invested in R&D in the Spanish biotechnology sector, 6.6% more than in 2015. The main area of activity is human health (66.8%), followed by food (23.5%). Most companies in the sector are found in the autonomous community of Catalonia (19.3%), followed by Andalusia (13.5%) and Galicia (8.6%).

More news

March 07, 2019

European Health Catapult: a 2019 programme launching innovative health start-ups

This training programme and competition is open to innovative European health start-ups in three categories – Medtech, Biotech and Digital Health.

February 07, 2019

Eurostars: call for innovative projects led by SMEs

Eurostars is a public funding programme designed to propel R&D performing small and medium-sized enterprises.

January 24, 2019

Second edition of the Open Innovation Forum

The aim of the Open Innovation Forum is to give companies the chance to share the biggest challenges they face when it comes to their innovations.